Genelux

Genelux is a clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's proprietary CHOICE platform allows for the engineering of highly potent and tumor-selective vaccinia virus-based candidates designed to induce systemic anti-tumor immunity. Its lead product candidate, Olvi-Vec, is currently in a Phase 3 registrational trial for platinum-resistant/refractory ovarian cancer. Beyond its lead program, Genelux is advancing a pipeline of viral candidates for various solid tumor indications and diagnostic applications, leveraging deep expertise in virology and immunotherapy.